The ability of multimerized cyclophilin A to restrict retrovirus infection  by Javanbakht, Hassan et al.
07) 19–29
www.elsevier.com/locate/yviroVirology 367 (20The ability of multimerized cyclophilin A to restrict retrovirus infection
Hassan Javanbakht a, Felipe Diaz-Griffero a, Wen Yuan a, Darwin F. Yeung a, Xing Li a,
Byeongwoon Song a, Joseph Sodroski a,b,⁎
a Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, MA 02115, USA
b Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA
Received 10 January 2007; returned to author for revision 2 February 2007; accepted 13 April 2007
Available online 15 June 2007Abstract
In owl monkeys, the typical retroviral restriction factor of primates, TRIM5α, is replaced by TRIMCyp. TRIMCyp consists of the TRIM5 RING,
B-box 2 and coiled-coil domains, as well as the intervening linker regions, fused with cyclophilin A. TRIMCyp restricts infection of retroviruses,
such as human immunodeficiency virus (HIV-1) and feline immunodeficiency virus (FIV), with capsids that can bind cyclophilin A. The TRIM5
coiled coil promotes the trimerization of TRIMCyp. Here we show that cyclophilin A that is oligomeric as a result of fusion with a heterologous
multimer exhibits substantial antiretroviral activity. The addition of the TRIM5 RING, B-box 2 and Linker 2 to oligomeric cyclophilin A generated
a protein with antiretroviral activity approaching that of wild-type TRIMCyp. Multimerization increased the binding of cyclophilin A to the HIV-1
capsid, promoting accelerated uncoating of the capsid and restriction of infection.
© 2007 Elsevier Inc. All rights reserved.Keywords: Cyclophilin A; HIV-1; FIV; Retroviral capsid; Coiled-coil domain; Multimerization; Restriction; TRIM5; TRIMCypIntroduction
TRIM5αmediates early, post-entry blocks to the infection of
cells by retroviruses, including human immunodeficiency virus
(HIV-1) (Stremlau et al., 2004; Perron et al., 2004; Hatziioan-
nou et al., 2004; Keckesova et al., 2004; Yap et al., 2004).
TRIM5α is a member of a family of proteins that contain a
tripartite motif, hence the designation TRIM (Reymond et al.,
2001). The tripartite motif includes a RING domain, B-box 2
domain and coiled-coil (cc) domain; TRIM proteins have also
been called RBCC proteins. TRIM proteins exhibit the pro-
pensity to form cytoplasmic or nuclear bodies (Reymond et al.,
2001). Many cytoplasmic TRIM proteins contain a C-terminal
B30.2 or SPRY domain. The coiled-coil domain of TRIM5 is
necessary for multimerization (Javanbakht et al., 2005; Perez-
Caballero et al., 2005a). TRIM5α proteins from different spe-
cies have been shown to form trimers (Mische et al., 2005).⁎ Corresponding author. Department of Cancer Immunology and AIDS, Dana-
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or adjacent linker 2 (L2) region can disrupt trimerization
(Javanbakht et al., 2006). TRIM5α variants that restrict HIV-1
infection specifically interact with HIV-1 capsid–nucleocapsid
(CA–NC) complexes assembled in vitro (Stremlau et al.,
2006a; Li et al., 2006). An intact B30.2/SPRY domain, which is
thought to contact the capsid directly, and the ability to trimerize
are required for efficient TRIM5α interaction with HIV-1 CA–
NC complexes (Javanbakht et al., 2006; Stremlau et al., 2006a).
Trimerization may allow TRIM5α to interact with sites on the
surface lattice of the retroviral capsid that exhibit trimeric pseu-
dosymmetry (Mische et al., 2005). Significant gains in avidity
would accrue to the interactions of two oligomeric complexes
with compatible symmetry. Thus, TRIM5α trimerization contri-
butes to avidity for the retroviral capsid and to the ability to
restrict virus infection (Javanbakht et al., 2006; Stremlau et al.,
2006a).
In owl monkeys, TRIMCyp, which is the result of a retro-
transposition event, replaced the TRIM5 gene (Nisole et al.,
2004; Ribeiro et al., 2005; Sayah et al., 2004). The encoded
TRIMCyp protein contains the RBCC domains of TRIM5 fused
to cyclophilin A. TRIMCyp can restrict some retroviruses, in-
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capsid protein by the cyclophilin A moiety (Nisole et al., 2004;
Sayah et al., 2004; Towers et al., 2003). Robust TRIMCyp-
mediated restriction involves at least two functions: (1) capsid
binding, which occurs most efficiently for trimeric TRIMCyp
proteins that retain the coiled-coil and cyclophilin A domains,
and (2) an effector function that depends upon the B-box 2
domain (Diaz-Griffero et al., 2006). Although the cyclophilin A
moiety of TRIMCyp interacts at low affinity with the mono-
meric HIV-1 capsid protein, trimerization of TRIMCyp
mediated by its coiled coil contributes to the interaction with
the processed multimeric capsid (Diaz-Griffero et al., 2006).
Here we investigate the structural requirements for cyclophilin
A to function as a retroviral restriction factor. We created cyc-
lophilin A fusion proteins containing coiled coils derived from
the GCN4 transcription factor. GCN4 coiled coils were chosen
because they are structurally well characterized, can assume
different oligomerization states depending on previously de-
fined amino acid changes and are derived from a protein unre-
lated to TRIM proteins (Harbury et al., 1993; Lumb and Kim,
1995; Weissenhorn et al., 1997). We show that a multimeric
cyclophilin A protein can partially restrict retrovirus infection.
The efficient interaction of multimeric cyclophilin A with the
retroviral capsid complex promotes capsid uncoating and the
retrovirus-restricting ability of these multimers. The addition of
the TRIM5 RING, B-box 2 and Linker 2 (L2) regions to oligo-
meric cyclophilin A generated a restriction factor with a potency
approaching that of TRIMCyp.
Results
Construction of multimeric cyclophilin A
To investigate the effect of multimerization on cyclophilin A
(CypA), we constructed chimeric proteins containing elements
of TRIMCyp, including the CypA moiety, fused with GCN4
variants that form either trimers or dimers (Harbury et al., 1993;
Lumb and Kim, 1995; Weissenhorn et al., 1997). The following
proteins were designed: (1) RBGCN4TriL2Cyp, in which the
coiled-coil domain of TRIMCyp has been replaced by a
heterologous trimeric coiled coil derived by modification of the
GCN4 transcription factor (Harbury et al., 1993; Lumb and
Kim, 1995; Weissenhorn et al., 1997); (2) RBGCN4TriCyp, a
construct in which the coiled coil and Linker 2 regions of
TRIMCyp are replaced by the trimeric GCN4 coiled-coil; (3)
GCN4TriL2Cyp, which consists of a trimeric GCN4 motif
fused at the N-terminus of the Linker 2 (L2) region of TRIM-
Cyp; (4) GCN4TriCyp, which consists of a trimeric GCN4
motif fused at the N-terminus of the cyclophilin A domain of
TRIMCyp; (5) GCN4DiCyp, which contains a dimeric GCN4
motif at the N-terminus of the cyclophilin A domain of TRIM-
Cyp; and (6) CypA, the monomeric cyclophilin A moiety of the
TRIMCyp protein (Fig. 1A).
All of the proteins, as well as rhesus monkey TRIM5α
(TRIM5αrh) as a control, were expressed stably in Cf2Th canine
thymocytes. The CypA, TRIMCyp, TRIM5α and GCN4 fusion
proteins have an influenza hemagglutinin (HA) epitope tag attheir carboxyl termini. All of the proteins were expressed at
least as well as the wild-type TRIMCyp proteins; CypA was
expressed at a level higher than those observed for the fusion
proteins and wild-type TRIMCyp (Fig. 1B).
To examine the oligomerization state of the CypA and the
GCN4 fusion proteins, cross-linking with increasing concen-
trations of ethylene glycol-bis(succinimidyl succinate) (EGS)
was employed. CypA exhibited only monomers, even at high
concentrations of cross-linker (Fig. 2A). The GCN4DiCyp
protein efficiently formed dimers. Cross-linked dimers of the
GCN4TriCyp protein were evident; trimers and higher order
forms of GCN4TriCyp were less efficiently cross-linked.
RBGCN4TriCyp exhibited trimers and higher order multimers
after cross-linking. GCN4DiCyp and GCN4TriL2Cyp exhibited
evidence of dimer formation (Fig. 2B). The RBGCN4TriL2Cyp
exhibited trimeric and higher order forms after cross-linking.
The wild-type TRIMCyp protein cross-linked into trimers. Thus,
all of the fusion proteins oligomerize.
We examined the subcellular localization of TRIMCyp,
CypA, GCN4DiCyp and the fusion proteins by staining cells
expressing these proteins with an antibody directed against the
HA epitope tag. As previously demonstrated (Diaz-Griffero
et al., 2006; Perez-Caballero et al., 2005b), TRIMCyp formed
cytoplasmic bodies and also exhibited diffuse cytoplasmic stain-
ing (Fig. 2C). In contrast to the wild-type TRIMCyp protein, the
CypA protein exhibited a diffuse pattern of expression through-
out the cells. The intracellular localization of RBGCN4-
TriL2Cyp was very similar to that of wild-type TRIMCyp.
Diffuse intracellular localization, in some cases with nuclear
exclusion, was seen for RBGCN4TriCyp, GCN4TriL2Cyp,
GCN4TriCyp and GCN4DiCyp. The intensity of the staining
reflected the protein expression level (see Fig. 1B). These results
indicate that artificial multimerization is compatible with
cytoplasmic localization of the CypA protein.
The ability of multimeric cyclophilin A protein to restrict
retrovirus infection
We examined the ability of the cyclophilin A fusion
proteins to inhibit infection by retroviruses that are sensitive to
TRIMCyp restriction (Diaz-Griffero et al., 2006). Cf2Th
canine thymocytes expressing TRIM5αrh, TRIMCyp, CypA,
RBGCN 4-TriL2Cyp, RBGCN4TriCyp, GCN4TriL2Cyp,
GCN4TriCyp and GCN4DiCyp or transduced with the
empty LPCX vector were challenged with VSV G glycopro-
tein-pseudotyped recombinant retroviruses (HIV-1-GFP and
FIV-GFP) expressing green fluorescent protein (GFP). As an
indicator of successful infection, GFP-positive cells were
scored (Fig. 3A). Cells expressing TRIMCyp and TRIM5αrh
proteins potently resisted HIV-1 infection, whereas cells
expressing CypA were infected at least as well as the control
cells transduced with the empty LPCX vector. Cf2Th cells
expressing GCN4TriCyp and GCN 4-DiCyp exhibited a
partial block to HIV-1 infection. RBG CN4TriCyp inhibited
HIV-1 infection less efficiently than either GCN4TriCyp or
GCN4DiCyp. However, Cf2Th cells expressing GCN4TriL2-
Cyp and RBGCN4TriL2Cyp restricted HIV-1 more potently
Fig. 1. Structure and expression of wild-type cyclophilin A and oligomeric cyclophilin A proteins. (A) The wild-type owl monkey cyclophilin A protein is depicted,
aligned with the fusion proteins containing different oligomerization domains. The RING (R), B-box 2 (B), coiled-coil (CC) and Linker 2 (L2) regions are derived from
TRIMCyp. The GCN4 trimer and dimer sequences (Harbury et al., 1993; Lumb and Kim, 1995) are shown. The C termini of the proteins contain hemagglutinin (HA)
epitope tags. (B) Cf2Th cells were transduced with pLPCX vectors expressing the indicated proteins. Cell lysates were Western blotted and probed with antibodies
directed against either the HA epitope tag (top panels) or β-actin (bottom panels).
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A fusion with the heterologous dimeric or trimeric GCN4 motifs
was sufficient for some level of anti-HIV-1 activity, the addition
of the RING/B-box2 and Linker 2 (L2) sequences of TRIMCyp
increased the potency of the HIV-1 restriction.
The susceptibility of the Cf2Th cells expressing the various
constructs to infection by recombinant FIV-GFP is shown in
Fig. 3B. The wild-type TRIM5αrh and TRIMCyp proteins
potently restricted FIV infection. The Cf2Th cells expressing
CypA were slightly more susceptible to FIV infection than the
control cells transduced with the empty LPCX vector. All of the
multimeric cyclophilin proteins restricted FIV-GFP infection
with an efficiency at least as great as that seen for HIV-1
infection. A similar rank order of potency of the multimeric
proteins was observed for the two viruses; for example,
RBGCN4TriL2Cyp and GCN4TriL2Cyp exhibited the most
potent activity against both HIV-1 and FIV infections. Thus,
FIV-GFP infection is susceptible to restriction by multimeric
forms of cyclophilin A.The capsids of murine leukemia viruses, N-MLV and
B-MLV, are not known to bind cyclophilin A and thus these
viruses are not sensitive to TRIMCyp restriction (Perron et al.,
2004; Yap et al., 2004; Keckesova et al., 2004; Hatziioannou et
al., 2004; Nisole et al., 2004). To examine whether the
antiretroviral activity of the multimeric GCN4–CypA fusion
proteins is specific, we challenged Cf2Th cells expressing these
proteins with N-MLV-GFP and B-MLV-GFP. Cells expressing
TRIM5αrh or TRIMCyp were tested in parallel. Although
N-MLVinfection is potently restricted by TRIM5αhu, TRIM5αrh
only partially restricts N-MLV infection (Hatziioannou et al.,
2004; Perron et al., 2004; Stremlau et al., 2004; Yap et al.,
2004). As expected, partial inhibition of N-MLV infection was
observed in Cf2Th cells expressing TRIM5αrh (Fig. 3C).
Neither TRIMCyp nor the GCN4–CypA fusion proteins
inhibited N-MLV infection. None of the proteins tested affected
the efficiency of B-MLV infection (Fig. 3D). Apparently, multi-
merization of CypA promotes inhibitory activity against retro-
viruses like HIV-1 and FIV that bind CypA (Diaz-Griffero et al.,
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not bind CypA.
Multimeric CypA-mediated restriction requires CypA-capsid
interaction
To investigate whether the ligand-binding capability of the
cyclophilin A moiety in the fusion proteins contributes to the
observed retroviral restriction, we challenged Cf2Th cells
expressing the fusion proteins with HIV-1-GFP and FIV-GFP
in the presence of cyclosporine A. Cyclosporine A has been
shown to bind cyclophilin A and inhibit its binding to HIV-1
and FIV capsid proteins (Bosco and Kern, 2004; Diaz-Griffero
et al., 2006; Luban et al., 1993; Lin and Emerman, 2006). Fig.
4A shows that Cf2Th cells expressing TRIMCyp and GCN4–
CypA fusion proteins were infected by HIV-1 at least as
efficiently as the control cells transduced with the empty LPCX
vector. By contrast, TRIM5αrh retained most of its anti-HIV-1
activity in presence of cyclosporine A, as expected (Stremlau et
al., 2006b). Similar results were observed for FIV infection (Fig.
4B). We conclude that retroviral restriction by the multimericFig. 2. Oligomerization states of CypA, TRIMCyp and GCN4–CypA fusion protein
linked with increasing concentrations of EGS and were subjected to Western blotting
order (h) forms of the proteins are indicated. (C) Cf2Th cells stably expressing the ind
HA antibody, as described in Materials and methods. Representative confocal microCypA constructs requires a CypA domain capable of interacting
with its ligand, presumably the retroviral capsid in this case.
The ability of multimeric cyclophilin A constructs to bind
HIV-1 CA–NC complexes
TRIM5αrh and TRIMCyp gain significant avidity for the
retroviral capsid by virtue of the trimeric state (Diaz-Griffero et
al., 2006; Javanbakht et al., 2006). TRIM5αrh trimerization has
been suggested to facilitate multivalent association with the
HIV-1 capsid (Mische et al., 2005). To investigate the potential
contribution of multimerization to the interaction of cyclophilin
A with the HIV-1 capsid, we utilized a recently established
capsid-binding assay (Stremlau et al., 2006a) to evaluate the
multimeric cyclophilin A proteins. In this assay, HIV-1 capsid-
like complexes are assembled in vitro from purified HIV-1
capsid–nucleocapsid (CA–NC) proteins (Ganser et al., 1999).
After incubation with lysates from cells expressing a restriction
factor, the CA–NC complexes are allowed to sediment through
70% sucrose cushions. The restriction factor co-sediments
through the sucrose cushion only if it associates with the HIV-1s. (A, B) Lysates from 293T cells expressing the indicated proteins were cross-
with an anti-HA antibody. Monomeric (m), dimeric (d), trimeric (t) and higher
icated HA-tagged proteins were fixed and stained using an FITC-conjugated anti-
scopic images of the Cf2Th cells expressing the indicated proteins are shown.
Fig. 2 (continued).
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(Stremlau et al., 2006a; Diaz-Griffero et al., 2006), TRIMCyp
interacted efficiently with theHIV-1 CA–NC complexes (Fig. 5).
Cyclophilin A is known to interact with the HIV-1 capsid protein
monomer (Braaten et al., 1997; Franke et al., 1994; Bosco and
Kern, 2004), but the affinity of this interaction is low (Yoo et al.,
1997). Consistent with previous results (Diaz-Griffero et al.,
2006), the CypA interaction with the HIV-1 CA–NC complexes
was weak (compare Input and Bound in Fig. 5). By contrast, all
of the multimeric GCN4–CypA fusion proteins that we tested
exhibited a higher affinity for HIV-1 CA–NC complexes. Thesedata suggest that multimerization increases the avidity of CypA
fusion proteins for HIV-1 capsid complexes.
Disruption of the oligomerization of a multimeric CypA
construct
To confirm that multimerization of CypAwas responsible for
the observed increases in HIV-1 capsid binding and restriction,
we replaced three of the isoleucine residues important for tri-
merization of the GCN4 moiety in GCN4TriCyp with hydro-
philic residues. The GCN4TriCyp protein with isoleucines 15,
18 and 22 of trimeric GCN4 converted to serines is designated
MutGCN4TriCyp. The ability of the GCN4TriCyp protein to
form oligomers was dramatically reduced by the modification
of GCN4 isoleucine residues (Fig. 6A). The MutGCN4TriCyp
protein did not detectably bind HIV-1 CA–NC complexes (Fig.
6B) nor restrict HIV-1 infection (Fig. 6C). We conclude that
multimerization of CypA is important for efficient binding to
the HIV-1 capsid and HIV-1 inhibition.
Effect of a multimeric CypA protein on cytosolic HIV-1 capsids
Previous studies have suggested that retroviral capsids
undergo accelerated uncoating after they enter the cytosol of
cells expressing a restricting TRIM5α protein (Stremlau et al.,
2006a; Perron et al., 2007). To investigate whether TRIMCyp or
the RBGCN4TriL2Cyp protein, which both efficiently restrict
HIV-1 infection, might affect HIV-1 capsid stability, we exa-
mined the fate of the HIV-1 capsid in cells expressing these
proteins. Control cells transduced with the empty LPCX vector
and cells expressing TRIMCyp or RBGCN4TriL2Cyp were in-
cubated with recombinant HIV-1-GFP pseudotyped with the
VSV G glycoprotein or, as a negative control, lacking envelope
glycoproteins. In parallel, a mutant (G89A) HIV-1-GFP virus,
which is resistant to TRIMCyp restriction (Towers et al., 2003;
Sayah et al., 2004), was studied. Sixteen hours after virus-cell
incubation, the cells were lysed and the cell lysates analyzed for
particulate and soluble HIV-1 p24 capsid protein. No cytosolic
HIV-1 capsid protein was detected in cells incubated with viru-
ses lacking envelope glycoproteins, as expected (Fig. 7). Parti-
culate capsid proteins from the wild-type and G89A HIV-1-GFP
viruses were detected in the control LPCX cells. The amounts of
particulate wild-type HIV-1 capsid protein in the cytosol of cells
expressing TRIMCyp and RBGCN4TriL2Cyp were signifi-
cantly decreased. By contrast, the levels of particulate G89A
mutant HIV-1 capsid protein were comparable in the control
LPCX-transduced cells and the cells expressing the TRIMCyp
and RBGCN4TriL2Cyp proteins. We conclude that expression
of the TRIMCyp and RBGCN4TriL2Cyp proteins leads to
decreases in the amounts of particulate, cytosolic HIV-1 capsids
in the target cells.
Discussion
In this study, we investigated the effect of multimerization on
the ability of cyclophilin A to restrict retroviruses. We show that
multimerization of cyclophilin A is sufficient to allow some
Fig. 3. Effect of expression of CypA and fusion proteins on retroviral infection. Cf2Th cells expressing wild-type TRIM5αrh, TRIMCyp and variants of the cyclophilin A proteins, or control Cf2Th cells transduced with
the empty pLPCX vector, were incubated with various amounts of HIV-1-GFP (A), FIV-GFP (B), N-tropic murine leukemia virus (N-MLV) (C) or B-MLV (D). Infected, GFP-positive cells were counted by FACS. The
results of a typical experiment are shown. Similar results were obtained in three independent experiments.
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Fig. 4. CypA interaction with retroviral capsids is required for restriction activity. Cf2Th cells expressing the wild-type TRIM5αrh, TRIMCyp and variants of CypA
proteins, or control Cf2Th cells transduced with the empty pLPCX vector, were incubated with various amounts of HIV-1-GFP (A) and FIV-GFP (B) in presence of
5 mM cyclosporine A. Infected, GFP-positive cells were counted by FACS. The results of a typical experiment are shown. Similar results were obtained in three
independent experiments.
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FIV are restricted by TRIMCyp in a manner inhibitable by
cyclosporine A (Diaz-Griffero et al., 2006; Luban et al., 1993).
The inhibitory activity likely depends upon the interaction of
the CypA moiety with the retroviral capsid. Although cyclo-
philin A is known to interact with both the unprocessed HIV-1
Gag polyprotein and the processed capsid protein with low
affinity (Franke et al., 1994; Thali et al., 1994; Gamble et al.,
1996; Yoo et al., 1997), we show here that the ability of mul-
timeric cyclophilin A to restrict retroviruses correlates with an
increased avidity for the processed and assembled capsid. Mul-
timerization of CypA likely increases avidity for the assembled
retroviral capsid rather than creating a new mode of binding. In
support of this assertion, GCN4TriCypA and GCN4DiCypA
restrict the same subset of retroviruses (HIV-1, FIV) as TRIM-
Cyp. Moreover, the ability of the GCN4–CypA fusion proteins
to restrict these retroviruses is sensitive to cyclosporine A.
Although both TRIM5α and TRIMCyp are naturally
trimeric (Mische et al., 2005; Diaz-Griffero et al., 2006), we
did not observe significant differences between the ability of
GCN4TriCyp and GCN4DiCyp to restrict retroviruses.
GCN4TriCypA and GCN4DiCyp were designed to form
trimers and dimers, respectively. Trimeric restriction factors
may have an avidity advantage in interacting with thepseudosymmetric trimeric structures on the assembled retro-
viral capsid (Mische et al., 2005). One explanation for the
functional equivalence of GCN4TriCyp and GCN4DiCyp
could be that the GCN4TriCyp protein only inefficiently
forms trimers or that the trimers formed are unstable.
Multimerization apparently promotes retrovirus restriction by
increasing the association of CypAmoieties and the viral capsid.
This implies that an increased binding of CypA to the incoming
capsid may be detrimental to infection. Indeed, instances have
been reported where an abundance of CypA in the target cell
appears to inhibit HIV-1 infection (Yin et al., 1998; Hatziioannou
et al., 2005; Diaz-Griffero et al., 2006). In addition, qualitative
differences in capsid binding by CypA might be promoted by
multimerization. For example, the order in which the capsid
proteins are bound by CypA might influence whether an en-
hancement or an inhibition of viral replicative events ensues.
The potent HIV-1 restriction mediated by wild-type TRIM-
Cyp and the RBGCN4TriL2Cyp proteins was accompanied by a
decrease in particulate HIV-1 capsids in the cytosol. These results
are consistent with a growing body of evidence supporting
accelerated uncoating of the retroviral capsid as a mechanism of
TRIM5α-mediated restriction (Stremlau et al., 2006a; Perron et
al., 2007). That CypA oligomerization might also lead to
retrovirus restriction by accelerating capsid disassembly implies
Fig. 5. Specific association of TRIMCyp and CypA variants with HIV-1 CA–NC complexes. In vitro assembled CA–NC complexes (Ganser et al., 1999) were
mixed with 293T lysates containing TRIMCyp, cyclophilin A or the indicated cyclophilin A variants and layered onto 70% sucrose cushions before centrifugation.
In some experiments (left panel), CA–NC complexes were not added, serving as a negative control. Immediately prior to mixing, an aliquot of the cell lysate was
removed and blotted with α-HA antibodies to determine the steady-state expression levels of the different cyclophilin A variants (Input). After centrifugation, the
pellet was resuspended in SDS sample buffer and analyzed by Western blotting using an anti-HA antibody (for Bound protein) or an anti-p24 antibody (to detect
CA–NC).
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prolyl isomerase activity. In this model, multimerization of CypA
results in an increased efficiency of capsid binding and augments
the consequences of CypA-capsid association. Such a model
explains why multimerization of the TRIM5α B30.2(SPRY)
domain is apparently insufficient for retrovirus restriction. For
example, TRIM5α proteins with certain B-box 2 domain
alterations trimerize and bind retroviral capsids efficiently, yet
are devoid of restricting activity (Javanbakht et al., 2005; Diaz-
Griffero et al., 2006; Perez-Caballero et al., 2005a; Stremlau et
al., 2006a; Diaz-Griffero et al., submitted for publication). Of
interest, expression of these B-box 2 mutants of TRIM5α in
target cells does not result in accelerated uncoating of the capsids
of retroviruses infecting those cells (Perron et al., 2007; Diaz-
Griffero et al., submitted for publication). Thus, a B-box 2
domain function appears to be essential for TRIM5α-mediated
capsid disassembly and viral restriction, perhaps by recruiting
cellular cofactors. By contrast, RING and B-box 2 functions are
not absolutely essential for TRIMCyp-mediated retroviral
restriction, although they contribute to the efficiency of the
restriction. A capsid-uncoating/restriction activity intrinsic to
the CypA domain itself would explain the different dependen-
cies of TRIM5α and CypA-based restriction factors on the B-
box 2 domain and associated cellular cofactors.
The RBGCN4TriCyp and GCN4TriCyp proteins, although
able to restrict infection by HIV-1 and FIV, did so less effi-ciently than TRIMCyp. The addition of the Linker 2 (L2) region
to these proteins augmented their restricting ability for both
HIV-1 and FIV. The Linker 2 region plays a major role in tri-
merization of TRIM5α(Javanbakht et al., 2006) and may mo-
dulate the spatial relationship of the CypA moiety with the
remainder of the TRIMCyp protein. The phenotypes with res-
pect to restriction enhancement for the RING/B-box 2 and L2
additions were interdependent, consistent with such a structural
interaction. The precise role played by the RING and B-box 2
domains and the Linker 2 region in retrovirus restriction by
TRIMCyp and TRIM5α is a subject for further investigation.
Materials and methods
Plasmid construction
The plasmids expressing the wild-type and mutant TRIM-
Cyp proteins were constructed using PCR-directed mutagen-
esis. The TRIMCyp cDNAwas PCR-amplified (Stremlau et al.,
2004) and digested with EcoRI and ClaI, sites that were intro-
duced by each of the PCR primers. These fragments were
cloned into the EcoRI and ClaI sites of pLPCX (Stratagene).
The trimeric GCN4 protein sequence reads as follows: MKQIE-
DKIEEIESKIKKIENEIARIKKLIGEG. The MutGCN4TriCyp
protein has an altered GCN4 sequence: MKQIEDKIEEIESK-
SKKSENESARIKKLIGEG.
Fig. 6. Effects of disruption of oligomerization of the GCN4TriCyp protein. (A) The oligomerization of the GCN4TriCyp and Mut GCN4TriCyp proteins was studied
by EGS cross-linking and SDS–PAGE.Monomeric (m), dimeric (d), trimeric (t) and higher order (h) forms of the proteins are indicated. (B) Cell lysates containing the
indicated proteins were incubated with HIV-1 CA–NC complexes. The mixtures were pelleted through 70% sucrose cushions. The amount of each protein in the input
lysate and the CA–NC-bound pellet is shown. The amount of HIV-1 CA–NC protein detected in the pellet is shown in the bottom row. (C) Cf2Th cells expressing the
indicated proteins or control LPCX-transduced cells were exposed to recombinant HIV-1-GFP. The percentage of GFP-positive cells at 72 h after virus-cell incubation
is shown. The experiment was repeated with comparable results.
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Retroviral vectors encoding wild-type or mutant TRIMCyp
proteins were created using the pLPCX plasmid (Stremlau et al.,
2004). The LPCX vectors contain only the amino-acid-coding
sequence of the TRIMCyp variants. Recombinant viruses were
produced in 293T cells by cotransfecting the pLPCX plasmids
with the pVPack-GP and pVPack-VSV-G packaging plasmids
(Stratagene). The pVPack-VSV-G plasmid encodes the vesi-
cular stomatitis virus (VSV) G envelope glycoprotein, which
allows efficient entry into a wide range of vertebrate cells (Yee
et al., 1994). The resulting virus particles were used to transduce
approximately 1×106 Cf2Th cells in the presence of 5 μg/ml
polybrene. Cells were selected in 5 μg/ml puromycin (Sigma).
Infection with viruses expressing green fluorescent protein
(GFP)
Recombinant HIV-1, FIV, N-MLV and B-MLV expressing
GFP were prepared as described (Stremlau et al., 2004). HIV-1
viral stocks were quantified by measuring reverse transcriptase(RT) activity. For infections, 3×104 Cf2Th cells seeded in 24-
well plates were incubated in the presence of virus for 24 h. Cells
were washed and returned to culture for 48 h and then subjected
to FACS analysis with a FACScan (Becton Dickinson).
Capsid-binding assay
Purification of the HIV-1 CA–NC protein expressed in E.
coli was carried out as previously described (Ganser et al.,
1999). High-molecular-weight HIV-1 capsid complexes were
assembled using 300 μM CA–NC protein and 60 μM (TG)50
DNA oligonucleotide in a volume of 100 microliters of 50 mM
Tris–HCl (pH 8.0) and 500 mM NaCl. The reaction was
allowed to proceed overnight at 4 °C, and the assembled CA–
NC complexes were stored at 4 °C until needed.
For a source of TRIMCyp and GCN4–CypA fusion proteins,
106 293T cells seeded in a 6-well dish were transfected with
1 μg of the appropriate pLPCX plasmid, using Lipofectamine
2000. Forty-eight hours later, the cells were harvested in PBS
containing 5 mM EDTA and resuspended in 250 μl of hypo-
tonic lysis buffer (10 mM Tris–HCl, pH 8.0, 10 mMKCl, 1 mM
Fig. 7. Fate of the wild-type and G89A HIV-1 capsids in target cells expressing
TRIMCyp and RBGCN4TriL2Cyp. VSV G-pseudotyped, wild-type (wt) HIV-
1-GFP and mutant HIV-1-GFP containing a G89A capsid change were incu-
bated with Cf2Th cells expressing TRIMCyp or RBGCN4TriL2Cyp, or control
cells transduced with the empty LPCX vector. In parallel, LPCX-transduced
cells were exposed to these viruses lacking envelope glycoproteins (Env−).
Sixteen hours later, the cells were lysed and the cell lysates were analyzed on
50% sucrose cushions, as described (Stremlau et al., 2006a). The HIV-1 p24
capsid protein detected in the particulate fraction (Pellet) and supernatant (Sup.)
is shown.
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using a 2-ml Dounce homogenizer (Pestle B, 15 strokes) and the
cell debris removed by centrifugation at 4 °C for 10 min at
maximum speed (14,000×g) in an Eppendorf microfuge. Fifty
microliters of lysate was saved for assessment of the input
amount of TRIMCyp or CypA derivative in the assay. Two-
hundred microliters of the cleared cell lysate were combined
with 5 μl of HIV-1 CA–NC complexes from the assembly
reaction and the concentration of NaCl adjusted to 150 mM. The
mixture was incubated for 1 h at room temperature with gentle
mixing. After incubation, the mixture was layered onto a 2-ml
70% sucrose cushion (prepared in 1× PBS) and centrifuged at
110,000×g for 1 h at 4 °C in a Beckman SW55Ti rotor. The
pellet was resuspended in 50 μl of 1× SDS sample buffer and
subjected to SDS–PAGE and Western blotting.
Protein analysis
Cellular proteins were extracted with radioimmunoprecipita-
tion assay (RIPA) buffer (10 mM Tris, pH 7.4; 100 mM NaCl;
1% sodium deoxycholate; 0.1% sodium dodecyl sulfate [SDS];
1% NP-40; 2 mg of aprotinin/ml; 2 mg of leupeptin/ml; 1 mg of
pepstatin A/ml; 100 mg of phenylmethylsulfonyl fluoride/ml).
The cell lysates were analyzed by SDS–PAGE (10% acryla-
mide), followed by blotting onto nitrocellulose membranes
(Amersham Pharmacia Biotech). Detection of protein by Wes-
tern blotting utilized monoclonal antibodies that are specifically
reactive with the HA (Roche) or V5 (Invitrogen) epitope tags,
and monoclonal antibodies to β-actin (Sigma). Detection of
proteins was performed by enhanced chemiluminescence (NEN
Life Sciences Products), using the following secondary antibo-dies obtained from Amersham Pharmacia Biotech: anti-mouse
(β-actin) and anti-rat (for HA).
Cross-linking
The HA-tagged proteins were expressed transiently in 293T
cells or stably in Cf2Th cells. Cells were washed in phosphate-
buffered saline (PBS) and lysed in NP40 lysis buffer (0.5%
Nonidet P40 (NP40), 1× protease inhibitor (complete EDTA-
free, Roche Diagnostics) in PBS) for 45 min at 4 °C. Lysates
were centrifuged at 14,000×g for 15 min at 4 °C. The cleared
lysates were not stored or frozen but rather were directly cross-
linked. Approximately 100–200 μl of cleared lysates were
diluted with PBS/1 mM EDTA to a final volume of 400 μl.
Lysates were cross-linked with varying concentrations (up to
2 mM) of ethylene glycol-bis(succinimidyl succinate) (EGS) for
30 min at room temperature and centrifuged briefly in a table-
top centrifuge. The reaction mix was quenched with 0.1 M
Tris–HCl, pH 7.5, and briefly centrifuged. The cleared, cross-
linked lysates were precipitated with the anti-HA antibody
HA.11 (Covance) and protein A-Sepharose beads (Amersham)
for 2 h at 4 °C; final volumes for the immunoprecipitation were
greater than 700 μl. The beads were washed four times with
NP40 wash buffer (10 mM Tris–HCl, pH 7.5, 0.5 M NaCl,
0.5% NP40) and boiled in LDS sample buffer (106 mM Tris–
HCl, 141 mM Tris Base, pH 8.5, 0.51 mM EDTA, 10%
glycerol, 2% LDS, 0.22 mM SERVA Blue G250, 0.175 mM
phenol red; Invitrogen) with a final concentration of 1.2% β-
mercaptoethanol (β-ME) for 10 min. Precipitated proteins were
separated on 8% or 12% Tris–glycine gels, transferred to a
PVDF membrane and detected with the horseradish peroxidase-
conjugated 3F10 anti-HA antibody (Roche Diagnostics) and the
ECL Plus Western Blotting Detection System (Amersham).
Immunofluorescence confocal microscopy
Cf2Th cells expressing the HA epitope-tagged TRIMCyp,
CypA or variant CypA proteins were grown overnight on Lab-
Tek II Chamber Slides (Nalge Nunc International). Following
fixation for 15 min in Cytofix/Cytoperm (BD Biosciences) and
permeabilization for 15 min in Perm/Wash (BD Biosciences),
the cells were incubated for 1 h with rat anti-HA 3F10 antibody
(Roche). The cells were then incubated with anti-rat IgG
conjugated with FITC (Santa Cruz) to detect the expression of
the TRIMCyp or CypAvariants and were examined by confocal
fluorescence microscopy.
Fate-of-capsid assay
The assay to examine the fate of HIV-1 capsids in the cytosol
of control and TRIMCyp-expressing cells was performed as
described by Stremlau et al., 2006a.
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